Skip to content
Research Article Open access CC BY 4.0

Therapeutic Use of Stem Cells in the Management of Coronary Artery Disease and Heart Failure; Current Trends, Progress, and Challenges

Esther Akinola, Faith Ikpenwmosa Itua, Olayinka Afolayan-Oloye, Adedeji Okikiade, Eesmael Adigun Oloye

Cardiology and Angiology: An International Journal · pp. 392–415 · Published 7 Nov 2022

10.9734/ca/2022/v11i4294

Abstract

In recent years, stem cell therapy has been considered a novel therapy for human subjects with coronary artery disease and heart failure. While stem cells of different types have been successfully isolated in laboratory settings and transplanted into animal models, doubts still exist on the successful outcome of stem cell therapy for cardiomyocyte regeneration in human subjects who develop coronary artery disease and heart failure.  Given the limited progress on stem cell therapy for this indication in human subjects, we aim to understand normal cardiomyocyte embryogenesis and apply it as a guide in identifying an ideal stem choice, critical growth, and transcription factors for cardiomyocyte regeneration as well as in the implementation of stem cell therapy for in human subjects with coronary artery disease and heart failure. Ethical limitations, safety, and long-term complications are critical in identifying the ideal stem cell choice. The route of infusion of the ideal stem cell, dose, and timing of administration must also be standardized for a favorable clinical outcome.  All stem cell sources evaluated for this clinical indication in animal and human studies were associated with some level of structural remodeling and improved cardiac performance following infusion. In the search for and identification of the ideal stem cell type, ethical choices with limited complications of restenosis, arrhythmias, ischemic vasculopathy, graft rejection, and malignant transformation would therefore rank high for the successful implementation of the therapeutic use of stem cells in the management of coronary artery disease and heart failure in human subjects. Original research and review articles from March 1995 – March 2022 were searched online. Search engines included Google Scholar, PubMed, Web of Science, and National Institute of Health. The keywords for the literature search included the use of stem cells for treatment, stem cell therapy, coronary artery disease, coronary heart disease, ischemic heart disease, and heart failure. Manual searches were also conducted for articles related to the pool generated from the online search. Statistical data were obtained from American Heart Association, Center for Disease Control (CDC), World Health Organization (WHO), and clinicaltrials.gov. From the articles generated, relevant sections were reviewed to understand the progress made with the therapeutic use of stem cells for managing coronary artery disease and heart failure in human subjects.  The sources of stem cells, transcription factors, isolation methods, routes, and timing of infusion of different stem cell types evaluated for this clinical indication in preclinical and clinical studies were reviewed and outlined.  The clinical outcomes of using different types of stem cells from both studies were also reviewed and compared, as well as ethical limitations, study limitations, and resultant adverse effects.

Heart failure coronary artery disease stem cells

References (59)

  1. 1 Bone marrow cells regenerate infarcted myocardium [DOI]
  2. 2 Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial [DOI]
  3. 3 Intracoronary Bone Marrow–Derived Progenitor Cells in Acute Myocardial Infarction [DOI]
  4. 4 Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial [DOI]
  5. 5 Building the mammalian heart from two sources of myocardial cells [DOI]
  6. 6 Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells [DOI]
  7. 7 Cardiac Stem Cells and Mechanisms of Myocardial Regeneration [DOI]
  8. 8 Transplanted Adult Bone Marrow Cells Repair Myocardial Infarcts in Mice [DOI]
  9. 9 Engraftment, Differentiation, and Functional Benefits of Autologous Cardiosphere-Derived Cells in Porcine Ischemic Cardiomyopathy [DOI]
  10. 10 Wharton’s Jelly-Derived Mesenchymal Stem Cells: Phenotypic Characterization and Optimizing Their Therapeutic Potential for Clinical Applications [DOI]
  11. 11 First Experience in Humans Using Adipose Tissue–Derived Regenerative Cells in the Treatment of Patients With ST-Segment Elevation Myocardial Infarction [DOI]
  12. 12 Transcriptional Regulation of Vertebrate Cardiac Morphogenesis [DOI]
  13. 13 Cardiac specific differentiation of mouse embryonic stem cells [DOI]
  14. 14 Intracoronary infusion of Wharton’s jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trial [DOI]
  15. 15 Transplantation of Adipose Derived Stromal Cells is Associated with Functional Improvement in a Rat Model of Chronic Myocardial Infarction [DOI]
  16. 16 Origins and Fates of Cardiovascular Progenitor Cells [DOI]
  17. 17 Resident cardiac progenitor cells: At the heart of regeneration [DOI]
  18. 18 Stem cell therapy for ischemic heart diseases [DOI]
  19. 19 The Past, Present and Future of Heart Transplantation [DOI]
  20. 20 Cardiac progenitor cells for heart repair [DOI]
  21. 21 Progenitor cells isolated from the human heart: a potential cell source for regenerative therapy [DOI]
  22. 22 Human Cardiac Stem Cells Isolated from Atrial Appendages Stably Express c-kit [DOI]
  23. 23 Myocyte proliferation in the developing heart [DOI]
  24. 24 Mesenchymal Stem Cell Therapy for Ischemic Heart Disease: Systematic Review and Meta-analysis [DOI]
  25. 25 Developmental origin and lineage plasticity of endogenous cardiac stem cells [DOI]
  26. 26 Derivation and cardiomyocyte differentiation of induced pluripotent stem cells from heart failure patients [DOI]
  27. 27 Transplantation of Mesenchymal Stem Cells Exerts a Greater Long-Term Effect than Bone Marrow Mononuclear Cells in a Chronic Myocardial Infarction Model in Rat [DOI]
  28. 28 The Promise and Challenge of Induced Pluripotent Stem Cells for Cardiovascular Applications [DOI]
  29. 29 Adipose-Derived Cells [DOI]
  30. 30 Therapeutic Use of Stem Cells for Myocardial Infarction [DOI]
  31. 31 Wharton’s Jelly or Bone Marrow Mesenchymal Stromal Cells Improve Cardiac Function Following Myocardial Infarction for More Than 32 Weeks in a Rat Model: A Preliminary Report [DOI]
  32. 32 Human-Induced Pluripotent Stem Cell Technology and Cardiomyocyte Generation: Progress and Clinical Applications [DOI]
  33. 33 Common Expression of Stemness Molecular Markers and Early Cardiac Transcription Factors in Human Wharton's Jelly-Derived Mesenchymal Stem Cells and Embryonic Stem Cells [DOI]
  34. 34 Stem cell therapies for myocardial infarction in clinical trials: bioengineering and biomaterial aspects [DOI]
  35. 35 Cardiac progenitor cells application in cardiovascular disease [DOI]
  36. 36 Intracoronary Bone Marrow–Derived Progenitor Cells in Acute Myocardial Infarction [DOI]
  37. 37 Cardiomyocyte proliferation in zebrafish and mammals: lessons for human disease [DOI]
  38. 38 Stem Cell Therapy for Heart Failure [DOI]
  39. 39 Stem Cell Therapy in Acute Myocardial Infarction: A Pot of Gold or Pandora's Box [DOI]
  40. 40 Microcirculation and Heart Failure [DOI]
  41. 41 Molecular pathways in myocardial development: a stem cell perspective [DOI]
  42. 42 Advances in stem cell therapy for cardiovascular disease (Review) [DOI]
  43. 43 Endogenous cardiac stem cells for the treatment of heart failure [DOI]
  44. 44 Role of KATP Channels in Beneficial Effects of Exercise in Ischemic Heart Failure [DOI]
  45. 45 Stem Cell Therapy for Myocardial Infarction: Challenges and Prospects [DOI]
  46. 46 Stem cell therapy for myocardial infarction [DOI]
  47. 47 Regulation of Coronary Blood Flow [DOI]
  48. 48 Signaling and Transcriptional Networks in Heart Development and Regeneration [DOI]
  49. 49 Cardiac muscle regeneration: lessons from development [DOI]
  50. 50 Polarity in Stem Cell Division: Asymmetric Stem Cell Division in Tissue Homeostasis [DOI]
  51. 51 Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association [DOI]
  52. 52 Ischemic Heart Disease Pathophysiology Paradigms Overview: From Plaque Activation to Microvascular Dysfunction [DOI]
  53. 53 Stem Cell Therapy in Heart Diseases – Cell Types, Mechanisms and Improvement Strategies [DOI]
  54. 54 OPTN/SRTR 2020 Annual Data Report: Heart [DOI]
  55. 55 Development of the human heart [DOI]
  56. 56 Stem cells as therapy for heart disease: iPSCs, ESCs, CSCs, and skeletal myoblasts [DOI]
  57. 57 Genomic Instability of iPSCs and Challenges in Their Clinical Applications [DOI]
  58. 58 Cardiac Cell Therapy: Insights into the Mechanisms of Tissue Repair [DOI]
  59. 59 Stem Cell Therapy for the Treatment of Myocardial Infarction: How Far Are We Now? [DOI]

Cited by 2

Therapeutic Potential and Mechanisms of Mesenchymal Stem Cells in Coronary Artery Disease: Narrative Review

Tejas Patel, Jana Mešić, Shai Meretzki · International Journal of Molecular Sciences · 2025

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

52

Page views

0

PDF downloads

20

Outbound clicks

2

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.